William Garrett Nichols is Chief Medical Officer at Candel Therapeutics, Inc. (CADL). They have made 5 open-market trades across 1 company since 2024, most recently 2025-07-28.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CADL | 52,493 | $429K |
Shares reported on the most recent Form 4, priced at the 2025-07-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CADL | SELL · 10b5-1 | 2025-07-28 | 2025-07-30 | $6.98 | $7K | -3.3% | -9.8% | -12.8% |
| CADL | SELL · 10b5-1 | 2025-06-30 | 2025-07-02 | $5.04 | $4K | +26.3% | +27.1% | +3.0% |
| CADL | SELL · 10b5-1 | 2025-03-18 | 2025-03-20 | $8.76 | $794K | -33.3% | -46.0% | -41.1% |
| CADL | SELL | 2025-01-15 | 2025-01-17 | $7.23 | $151K | +2.1% | +39.6% | -33.0% |
| CADL | SELL | 2025-01-08 | 2025-01-10 | $8.22 | $178K | -13.1% | +6.8% | -41.3% |
| CADL | SELL | 2024-11-29 | 2024-12-03 | $4.56 | $127K | +45.2% | +93.3% | +70.1% |
| CADL | SELL | 2024-07-17 | 2024-07-19 | $6.47 | $141K | -1.3% | -12.6% | -2.3% |
| CADL | SELL | 2024-07-11 | 2024-07-15 | $5.97 | $117K | -1.5% | -20.4% | -9.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.